Clin2
NCT05854667Possibly a fitRecruiting

High-dose lisdexamfetamine with rewards for meth use changes

Methamphetamine AbuseMethamphetamine-dependenceAddiction, SubstanceAddiction

Part of Mental health clinical trials.

This Phase 2 study tests high-dose lisdexamfetamine (a prescription stimulant) to help people reduce or stop methamphetamine use. It also uses “contingency management” (rewards tied to meeting goals) to encourage treatment participation and lower use.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
440 people
Ages
18 years to 55 years
Study type
Interventional

Who can take part

  • You are 18 to 55 years old
  • You have a moderate-to-severe methamphetamine use problem (diagnosed using DSM-5 criteria)
  • In the past 28 days, you used meth at least 14 days, and a urine test also shows meth-related breakdown products
  • You want to reduce or stop meth use
  • You can join random assignment (you may get different study treatments) and stay for the whole study
  • You can communicate in English or French and provide consent

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06788587Recruiting· Phase 2
Long-term stimulant for methamphetamine recovery

This study tests whether a high dose of a stimulant medication (lisdexamfetamine, an ADHD medicine) taken over many weeks can help people who have already completed a methamphetamine treatment program to stay off meth, reduce use, or avoid relapse.

Montreal, Quebec
NCT06721494Recruiting· Phase 2
A single-dose study of CS-1103 for methamphetamine use

This trial tests a single dose of an investigational drug, CS-1103, to see if it is safe and effective for people who use methamphetamine. It may help understand how the drug affects methamphetamine in the body.

Glendale, California
NCT07204249Recruiting· Phase 2
Testing a diabetes drug to help stop meth use

This study tests whether a medication called 'Glutide' (a GLP-1 agonist, similar to drugs used for diabetes) can help people who want to stop or cut down on methamphetamine. It's for those with moderate to severe meth use disorder who have used meth on at least 15 of the past 30 days.

San Francisco, California
NCT06666010Not yet recruiting· Phase 2
Psilocybin-assisted therapy for stimulant use disorder

This trial tests whether a single dose of psilocybin (PEX010) combined with therapy can help people stop using methamphetamine or other stimulants. It focuses on safety and early signs of effectiveness.

NCT05529927Recruiting· Phase 2
Dexamphetamine given long-acting to reduce cocaine use

This Phase 2 study tests whether a long-acting form of dexamphetamine can reduce cocaine use in people with moderate to severe cocaine use disorder. It also checks safety, including heart and mental health side effects, while you attend study visits regularly.

The Hague
NCT07774702Not yet recruiting· Phase 2
Psilocybin for methamphetamine use disorder

This trial tests whether a psychedelic drug called psilocybin can help people cut down or stop using methamphetamine. You'll take the drug in a supervised setting and get support to aim for full abstinence.

Birmingham, Alabama

Hear when a new Methamphetamine Abuse trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.